Journal of Diabetes Research

Journal of Diabetes Research / 2016 / Article

Research Article | Open Access

Volume 2016 |Article ID 7347065 |

Alessandro P. Delitala, Giovanni M. Pes, Hoda M. Malaty, Gavino Pisanu, Giuseppe Delitala, Maria P. Dore, "Implication of Cytotoxic Helicobacter pylori Infection in Autoimmune Diabetes", Journal of Diabetes Research, vol. 2016, Article ID 7347065, 6 pages, 2016.

Implication of Cytotoxic Helicobacter pylori Infection in Autoimmune Diabetes

Academic Editor: Carlos Martinez Salgado
Received11 Sep 2015
Accepted23 Nov 2015
Published28 Dec 2015


Background. Type 1 diabetes (T1D) and type 2 diabetes (T2D) have been linked to Helicobacter pylori infection, although results are conflicting. No previous study addressed a possible link between H. pylori infection and latent autoimmune diabetes in adults (LADA). In this study, a correlation among H. pylori infection and the risk of autoimmune diabetes in comparison with T2D was investigated. Methods. Sera from 234 LADA patients, 105 patients with late-onset T1D, and 156 patients with T2D were analyzed for anti-H. pylori and the cytotoxin-associated antigen (CagA) IgG antibodies. Results. H. pylori seroprevalence was comparable in LADA (52%), late-onset T1D (45%), and T2D (49%) with no gender differences. The seroprevalence of CagA IgG was significantly higher in autoimmune diabetes (late-onset T1D: 45%, LADA: 40%) compared to T2D (25%; ). Conclusions. Although H. pylori seroprevalence was similar in LADA, T1D, and T2D, anti-CagA positivity was significantly increased among patients with autoimmune diabetes, suggesting that more virulent H. pylori strains might be a trigger for immune mechanisms involved in their pathogenesis.

1. Introduction

Helicobacter pylori colonizes approximately 50% of the world’s population. Differences in prevalence relate to age, socioeconomic status, and geographic location [1, 2]. H. pylori infection is commonly associated with gastritis, gastric cancer, and peptic ulcer disease, as well as with a variety of extragastric manifestations [35]. The infection elicits a robust inflammatory response [6] that in turn may result in molecular mimicry, which may be responsible for some of the extragastric manifestations [4, 5]. Available data also suggests that H. pylori infection might be associated with diabetes mellitus.

The relationship between H. pylori infection and development of diabetes is thought to be possibly mediated by the long-standing chronic inflammation which has been implicated in insulin resistance [7, 8]. A recent prospective study demonstrated an association between H. pylori infection and the rate of incident diabetes [9]. The authors analyzed 782 Latinos over 60 years of age without diabetes living in California in 1998-1999. Sera were tested for antibodies against herpes simplex virus 1, varicella virus, cytomegalovirus, H. pylori, and Toxoplasma gondii. Subjects were followed up until June 2008 and the relative incidence rate of diabetes in relation to H. pylori IgG status was evaluated. Individuals positive for H. pylori infection at the enrollment time were 2.7 times more prone to develop diabetes than seronegative individuals [9].

There are several reports describing an association between H. pylori infection and autoimmune diseases [10]; however, evidence of a link with type 1 diabetes (T1D) is conflicting. For example, Pocecco et al. reported increased prevalence of H. pylori with age in young diabetics [11], while according to other studies the frequency of H. pylori infection in T1D was comparable to healthy controls [1214]. Moreover, an increased frequency of H. pylori reinfection following treatment in comparison to nondiabetic dyspeptic patients was observed, suggesting differences in susceptibility [15].

Latent autoimmune diabetes in adults (LADA) is a type of autoimmune diabetes that resembles T2D at onset. LADA represents 5–10% of subjects previously diagnosed as having T2D with which it shares some phenotypical features [16]. LADA is characterized by a later onset and slower progression towards insulin dependence than typical T1D.

The role of H. pylori infection in T2D is unclear [6, 12, 17] and it is still debated whether H. pylori has a pathogenic role or whether diabetic patients have an increased susceptibility to H. pylori infection. No previous studies have examined the association between LADA and H. pylori infection. Therefore, we investigated the prevalence of H. pylori infection in patients with autoimmune diabetes (both LADA and late-onset T1D), as well as nonautoimmune T2D.

2. Materials and Methods

2.1. Study Population

Demographic features of LADA patients from Sardinia recruited in this study have been reported previously [18, 19]. Briefly, a total of 5,568 Sardinian patients with T2D at diagnosis were screened for the presence of pancreatic islet autoantibodies. These patients have been referred to as a part of a prospective longitudinal multicenter study, among the major diabetic units of the island (Sassari, Cagliari, Nuoro, Oristano). From the original cohort of 251 patients, 17 subjects were excluded because their sera were no longer available. A total of 234 serum samples, 126 women and 108 men (median age at onset of diabetes was 54 years, range 30–86 years), were analyzed. Diagnostic criteria for latent autoimmune diabetes patients were (i) presence of circulating glutamic acid decarboxylase 65 antibodies (GAD65Ab), (ii) age at onset of diabetes above 30 years, and (iii) absence of insulin treatment for at least 8 months after diagnosis. In addition, none of the patients presented with ketoacidosis and/or significant weight loss [18].

According to the study design, serum samples from 105 late-onset T1D patients (55 males, 50 females, age range from 39 to 55 years) were also analyzed. Diagnostic criteria for late-onset T1D were sudden onset above the age of 30 and presence of ketoacidosis [18]. Sera from 156 (85 males and 71 females, range 48–77 years) type 2 diabetic patients who resulted to be GAD negative at the antibody screening were randomly selected as controls for comparison with autoimmune diabetes.

The study was approved by the local ethics committee and all participants provided signed informed consent to participate in the study.

2.2. Serologic Methods

Blood venous samples were collected between 7 and 8 a.m., after an overnight fast. Serum samples were stored at −80°C until being assayed. H. pylori status was evaluated by an enzyme-linked immunosorbent assay (ELISA) for anti-H. pylori immunoglobulin G (Helicobacter pylori IgG, ELISA kit, Genesis Diagnostics Ltd., Littleport, UK), with a reported sensitivity and specificity of 99.2% and 90.9%, respectively [20]. In addition, the presence of putative H. pylori virulence factor was assessed by a specific serological ELISA test for IgG antibodies against CagA (CagA IgG ELISA Kit, Genesis Diagnostics Ltd., Littleport, UK), with a sensitivity of 96%, specificity of 97%, and interassay coefficient of variation of <12% [20].

2.3. Genotyping of Immune-Related Gene Variants

HLA class II and CTLA-4 genotypes, previously associated with the immune response in LADA patients [18, 21], were also analysed in relation to H. pylori infection. In LADA patients, HLA class II genotypes, determined by dot-blot analysis [18], were ranked as low, intermediate, or high risk for diabetes. At least two high-risk haplotypes were necessary to classify a patient in the high-risk category; the presence of one high-risk and one permissive-neutral haplotype was taken as the hallmark of the intermediate-risk category whereas carriers of two copies of negatively associated haplotypes or combinations of negatively associated and neutral haplotypes were included in the low-risk category. In addition, a G6230A (rs3087243) functional polymorphism within the CTLA-4 gene, exhibiting regulatory properties on immune effector T cells, was also genotyped in LADA patients. (Patients carrying at least one G allele were classified as high risk whereas patients with no G allele were considered at low risk.) Further, a total score for genetic risk was calculated combining both the HLA (low, intermediate, and high risk) and CTLA (low, high risk) categories, namely, by giving 0 to 5 points to the six progressively rising risk levels resulting from paired HLA/CTLA-4 assortment. Prevalence of CagA antibodies positivity was stratified according to this score.

2.4. Methods of Analysis

Subjects who were positive for anti-H. pylori and CagA IgG antibodies were classified into 3 groups: (1) patients with T2D, (2) patients with late-onset T1D, and (3) patients with LADA. Differences in H. pylori prevalence were compared using Pearson test or Cochran-Armitage test for a linear trend in proportions. All statistical analyses were carried out using SPSS statistical software (version 16.0, Chicago, IL, USA) and values lower than 0.05 were considered statistically significant.

3. Results

From the total of 495 serum samples tested for H. pylori infection, there were 156 patients with T2D, 105 with late-onset T1D, and 234 with latent autoimmune diabetes. The overall seropositivity of H. pylori infection was 49% in the T2D group, 45% in T1D group, and 52% in LADA group (Table 1). There was no significant difference in the overall seroprevalence of H. pylori infection among males and females within each of the three groups. The previously described birth cohort effect in the acquisition of H. pylori infection was evident [22].

VariableType 1
Number (Hp%)
OR@ (95% CI)LADA
Number (Hp%)
OR@ (95% CI)Type 2
Number (Hp%)

Birth cohort (y)
1 (100)14 (43)0
 1930–193919 (68) 3.25 (0.43–24.84)52 (53)1.62 (0.25–10.51)5 (40)
 1940–194924 (50)0.68 (0.27–1.69)86 (58)0.86 (0.47–1.58)84 (54)
 1950–195924 (42)0.63 (0.24–1.69)50 (50)0.82 (0.37–1.80)48 (50)
 1960–196923 (39)1.93 (0.47–7.88)30 (47)2.63 (0.69–10.02)15 (27)
14 (14)6 (33)4 (0)
 Total105 (45)0.75 (0.46–1.23)234 (52)0.96 (0.64–1.43)156 (49)

 Male55 (44)0.74 (0.37–1.46)108 (52)1.01 (0.57–1.78)85 (54)
 Female50 (46)0.95 (0.46–1.96)126 (52)1.14 (0.64–2.02)71 (46)

Percentage positive for Helicobacter pylori infection.
@Odds ratio; confidence interval.

Among 245 who tested positive for H. pylori, 89 patients (36%) were positive for IgG antibody anti-CagA. Patients with autoimmune diabetes consistently had higher prevalence of CagA positive strains compared with T2D (Table 2). The prevalence of CagA antibodies increased linearly, though not significantly, based on the HLA/CTLA-4 score haplotypes, known to confer a high or intermediate risk of autoimmune diabetes. On the contrary, IgG anti-H. pylori did not vary significantly (Figure 1).

Autoimmune diabetesNonautoimmune diabetes
Type 1LADAType 2

Hp negative58 (55%)112 (48%)80 (51%)
Hp positive, CagA negative26 (25%)73 (31%)57 (37%)
Hp positive, CagA positive21 (20%)49 (21%)19 (12%)
CagA prevalence in Hp positive patients45%40%25%

Hp positive, autoimmune versus nonautoimmune diabetes: = 0.0055; .
CagA positive, autoimmune versus nonautoimmune diabetes: = 1.556; .
CagA positive/Hp positive, type 1 versus type 2 diabetes: = 5.125; .
CagA positive/Hp positive, LADA versus type 2 diabetes: = 4.775; .

4. Discussion

The link between H. pylori infection and diabetes remains controversial [17, 2330]. Although an increased susceptibility to H. pylori could explain its higher prevalence in patients with diabetes, both diseases could share common susceptibility genes.

In this study, we found that anti-CagA antibodies in LADA patients vary according to the presence of genetic variants previously associated with the risk of autoimmune diabetes. While differences in IgG anti-H. pylori prevalence were not significant across the HLA class II or CTLA-4 genotypes, CagA antibody prevalence was found to be higher, though not significantly. However, H. pylori virulence factor might confer a high or intermediate risk for autoimmune diabetes in carriers of HLA haplotypes and carriers of the CTLA-4 6230G allele (AG and GG genotypes). These results reflect what has already been observed in the case of anti-GAD65 antibodies whose levels were significantly increased in LADA patients carrying the high-risk HLA-DR3 haplotypes [31]. Similarly, it may be hypothesized that carriers of genetic variants, associated with an increased risk for autoimmune disease, may have an intrinsic predisposition also to develop a stronger immune response against infectious agents, including H. pylori, compared to subjects who do not carry the gene variants. This could be consistent with the findings of our study where the prevalence of CagA positivity increased with the number of HLA/CTLA-4-related genetic risks. The capacity of high-risk HLA and CTLA-4 gene variants to influence binding and later presenting autoantigens (including pancreatic beta cells) to autoreactive T lymphocytes [32], as well as the production of antibodies by B cells, may be different depending on the cell repertoire, resulting in distinct antibody response observed for anti-H. pylori and anti-CagA. This conjecture deserves to be tested in larger cohorts.

The Sardinian population is characterized by high prevalence of genetic disorders including T1D [33]. Similarly, very high prevalence of H. pylori has been demonstrated in healthy children and adults [34]. In a previous study, prevalence of H. pylori infection in diabetic patients (insulin-dependent, or type 1, and non-insulin-dependent, or type 2, diabetes mellitus) was compared with a healthy control group [12]. The diagnosis of diabetes was confirmed for at least one year earlier. H. pylori status was evaluated by using an ELISA for anti-H. pylori immunoglobulin G [12]. We found no significant differences in the prevalence of H. pylori infection in any age group; however, the prevalence of H. pylori was higher among healthy children than among children with T1D (25% versus 9%) [12]. Our current study also showed no difference in the prevalence of H. pylori infection between patients with autoimmune and nonautoimmune diabetes although prevalence of infection with more virulent strains was increased in patients with autoimmune diabetes. Impairment of cellular and humoral immunity in diabetic patients could enhance an individual’s susceptibility to acquire H. pylori infection [35] and altered glucose metabolism might facilitate H. pylori colonization in the gastric mucosa [36]. For example, diabetes-induced reduction of gastrointestinal motility and acid secretion may promote pathogen colonization and infection rate in the gut [9]. H. pylori infection may also contribute to the development of diabetes as the infection is associated with chronic low-grade inflammation with upregulation of cytokines such as C-reactive protein, tumor necrosis factor, and interleukin 1β, which may influence insulin action and pancreatic β cell secretion. In the same time, H. pylori-induced gastritis affects the secretion of gastric hormones, including leptin, ghrelin, gastrin, and somatostatin, which could affect insulin sensitivity and glucose homeostasis [3739]. H. pylori is one of the most infectious agents proposed as an agent triggering an autoimmune response and molecular mimicry is one of the several mechanisms that have been suggested in an attempt to explain the extraintestinal manifestations of H. pylori infections [3, 4]. Most H. pylori infected individuals produce antibodies to a variety of H. pylori antigens. An antibody response may also be seen against autoantigens, including IL-8, antral epithelium, homologous host, and bacterial epitopes (e.g., Lewis X, lipopolysaccharide, and heat shock protein) [40]. For example, H. pylori infection has been associated with the pathogenesis of autoimmune thrombocytopenia and autoimmune pancreatitis. A study showed homology with an amino acid sequence of plasminogen-binding protein (PBP) of H. pylori and with ubiquitin-protein ligase E3 component n-recognin 2, an enzyme highly expressed in acinar cells of the pancreas. Antibodies against the PBP peptide were detected in 95% of patients with autoimmune pancreatitis and in 10% of patients with pancreatic cancer [41].

CagA positive strains cause more intense tissue inflammation and cytokine production and are specifically related to the pathogenesis of autoimmune thrombocytopenia. More specifically, bacteria that express CagA are potent inducers of IL-8 [34]. CagA positivity is also associated with more severe clinical outcomes such as duodenal ulcers, precancerous lesions, and gastric cancer [42]. The increased prevalence of IgG anti-CagA in autoimmune diabetes might be related to possible cross-reactivity of IgG anti-CagA with host’s beta cell antigens. In fact, immunoreactivity of anti-CagA antibodies was demonstrated with many human antigens, such as vessel, smooth muscle cells, and fibroblasts-like cells in intimal atherosclerotic plaques [43, 44], and therefore it could also occur in the case of beta cell antigens. If this hypothesis is confirmed, it is tempting to speculate that patients who suffer from an infection by virulent CagA positive H. pylori strains may elicit an immune-mediated response against specific self-antigens, including those associated with pancreatic beta cells, thereby displaying increased susceptibility to autoimmune diabetes.

5. Conclusions

Although the cross-sectional design of the study does not permit discerning a cause-effect relationship between H. pylori infection and diabetes, higher prevalence of virulent strains was observed among patients with autoimmune diabetes. Prevention and progression of diabetes could be an additional long term benefit of H. pylori eradication.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Alessandro P. delitala and Giovanni M. Pes contributed equally to the work.


This work was done by using a grant from Regione Autonoma della Sardegna (Genetic and Immunologic Markers in the Pathogenesis of LADA and Type 2 Diabetes Mellitus), no. CRP-27076, Scientific Coordinator Professor Giuseppe Delitala.


  1. D. R. Cave, “How is helicobacter pylori transmitted?” Gastroenterology, vol. 113, no. 6, pp. S9–S14, 1997. View at: Publisher Site | Google Scholar
  2. F. Megraud, “Epidemiology of Helicobacter pylori infection,” Gastroenterology Clinics of North America, vol. 22, no. 1, pp. 73–88, 1993. View at: Google Scholar
  3. G. Realdi, M. P. Dore, and L. Fastame, “Extradigestive manifestations of Helicobacter pylori infection: fact and fiction,” Digestive Diseases and Sciences, vol. 44, no. 2, pp. 229–236, 1999. View at: Publisher Site | Google Scholar
  4. F. Franceschi, A. Tortora, G. Gasbarrini, and A. Gasbarrini, “Helicobacter pylori and extragastric diseases,” Helicobacter, vol. 19, no. 1, pp. 52–58, 2014. View at: Publisher Site | Google Scholar
  5. J. E. Crabtree, “Immune and inflammatory responses to Helicobacter pylori infection,” Scandinavian Journal of Gastroenterology—Supplement, vol. 215, pp. 3–10, 1996. View at: Google Scholar
  6. X. Zhou, C. Zhang, J. Wu, and G. Zhang, “Association between Helicobacter pylori infection and diabetes mellitus: a meta-analysis of observational studies,” Diabetes Research and Clinical Practice, vol. 99, no. 2, pp. 200–208, 2013. View at: Publisher Site | Google Scholar
  7. S. A. Polyzos, J. Kountouras, C. Zavos, and G. Deretzi, “The association between Helicobacter pylori infection and insulin resistance: a systematic review,” Helicobacter, vol. 16, no. 2, pp. 79–88, 2011. View at: Publisher Site | Google Scholar
  8. S. Aydemir, T. Bayraktaroglu, M. Sert et al., “The effect of Helicobacter pylori on insulin resistance,” Digestive Diseases and Sciences, vol. 50, no. 11, pp. 2090–2093, 2005. View at: Publisher Site | Google Scholar
  9. C. Y. Jeon, M. N. Haan, C. Cheng et al., “Helicobacter pylori infection is associated with an increased rate of diabetes,” Diabetes Care, vol. 35, no. 3, pp. 520–525, 2012. View at: Publisher Site | Google Scholar
  10. D. S. Smyk, A. L. Koutsoumpas, M. G. Mytilinaiou, E. I. Rigopoulou, L. I. Sakkas, and D. P. Bogdanos, “Helicobacter pylori and autoimmune disease: cause or bystander,” World Journal of Gastroenterology, vol. 20, no. 3, pp. 613–629, 2014. View at: Publisher Site | Google Scholar
  11. M. Pocecco, E. Buratti, A. Tommasini, G. Torre, and T. Not, “High risk of Helicobacter pylori infection associated with cow's milk antibodies in young diabetics,” Acta Paediatrica, vol. 86, no. 7, pp. 700–703, 1997. View at: Publisher Site | Google Scholar
  12. M. P. Dore, M. Bilotta, H. M. Malaty et al., “Diabetes mellitus and Helicobacter pylori infection,” Nutrition, vol. 16, no. 6, pp. 407–410, 2000. View at: Publisher Site | Google Scholar
  13. V. Kojecký, J. Roubalík, and N. Bartoníková, “Helicobacter pylori in patients with diabetes mellitus,” Vnitrni Lekarstvi, vol. 39, no. 6, pp. 581–584, 1993. View at: Google Scholar
  14. J.-T. Lin, J. T. Wang, T. H. Wang, M. S. Wu, T. K. Lee, and C. J. Chen, “Helicobacter pylori infection in a randomly selected population, healthy volunteers, and patients with gastric ulcer and gastric adenocarcinoma. A seroprevalence study in Taiwan,” Scandinavian Journal of Gastroenterology, vol. 28, no. 12, pp. 1067–1072, 1993. View at: Publisher Site | Google Scholar
  15. M. Candelli, D. Rigante, A. Schiavino et al., “High reinfection rate of Helicobacter pylori in young type 1 diabetic patients: a three-year follow-up study,” European Review for Medical and Pharmacological Sciences, vol. 16, no. 11, pp. 1468–1472, 2012. View at: Google Scholar
  16. P. Z. Zimmet, “The pathogenesis and prevention of diabetes in adults: genes, autoimmunity, and demography,” Diabetes Care, vol. 18, no. 7, pp. 1050–1064, 1995. View at: Publisher Site | Google Scholar
  17. A. Oluyemi, E. Anomneze, S. Smith, and O. Fasanmade, “Prevalence of a marker of active Helicobacter pylori infection among patients with type 2 diabetes mellitus in Lagos, Nigeria,” BMC Research Notes, vol. 5, article 284, 2012. View at: Publisher Site | Google Scholar
  18. M. Maioli, G. M. Pes, G. Delitala et al., “Number of autoantibodies and HLA genotype, more than high titers of glutamic acid decarboxylase autoantibodies, predict insulin dependence in latent autoimmune diabetes of adults,” European Journal of Endocrinology, vol. 163, no. 4, pp. 541–549, 2010. View at: Publisher Site | Google Scholar
  19. G. M. Pes, A. P. Delitala, A. Errigo, G. Delitala, and M. P. Dore, “Clustering of immunological, metabolic and genetic features in latent autoimmune diabetes in adults: evidence from principal component analysis,” Internal and Emergency Medicine, pp. 1–7, 2015. View at: Publisher Site | Google Scholar
  20. N. Figura, A. Palazzuoli, D. Vaira et al., “Cross-sectional study: CagA-positive Helicobacter pylori infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide,” Journal of Clinical Pathology, vol. 67, no. 3, pp. 251–257, 2014. View at: Publisher Site | Google Scholar
  21. A. P. Delitala, G. Fanciulli, M. Zoledziewska et al., “Allelic variant in CTLA4 is associated with thyroid failure and faster β-cell exhaustion in latent autoimmune diabetes in adults,” Journal of Diabetes, vol. 7, no. 1, pp. 68–73, 2015. View at: Publisher Site | Google Scholar
  22. M. P. Dore, G. Marras, C. Rocchi et al., “Changing prevalence of Helicobacter pylori infection and peptic ulcer among dyspeptic Sardinian patients,” Internal and Emergency Medicine, vol. 10, no. 7, pp. 787–794, 2015. View at: Publisher Site | Google Scholar
  23. B. R. Devrajani, S. Z. A. Shah, A. A. Soomro, and T. Devrajani, “Type 2 diabetes mellitus: a risk factor for Helicobacter pylori infection: a hospital based case-control study,” International Journal of Diabetes in Developing Countries, vol. 30, no. 1, pp. 22–26, 2010. View at: Publisher Site | Google Scholar
  24. A. Bener, R. Micallef, M. Afifi, M. Derbala, H. M. Al-Mulla, and M. A. Usmani, “Association between type 2 diabetes mellitus and Helicobacter pylori infection,” Turkish Journal of Gastroenterology, vol. 18, no. 4, pp. 225–229, 2007. View at: Google Scholar
  25. N. E. Gulcelik, E. Kaya, B. Demirbas et al., “Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy,” Journal of Endocrinological Investigation, vol. 28, no. 3, pp. 214–217, 2005. View at: Publisher Site | Google Scholar
  26. S. Bajaj, L. Rekwal, S. P. Misra, V. Misra, R. K. Yadav, and A. Srivastava, “Association of helicobacter pylori infection with type 2 diabetes,” Indian Journal of Endocrinology and Metabolism, vol. 18, pp. 694–699, 2014. View at: Google Scholar
  27. R. Anastasios, C. Goritsas, C. Papamihail, R. Trigidou, P. Garzonis, and A. Ferti, “Helicobacter pylori infection in diabetic patients: prevalence and endoscopic findings,” European Journal of Internal Medicine, vol. 13, no. 6, pp. 376–379, 2002. View at: Publisher Site | Google Scholar
  28. G. T. C. Ko, F. K. L. Chan, W.-B. Chan et al., “Helicobacter pylori infection in chinese subjects with type 2 diabetes,” Endocrine Research, vol. 27, no. 1-2, pp. 171–177, 2001. View at: Publisher Site | Google Scholar
  29. O. G. Stanciu, A. Trifan, C. Sfarti, C. Cojocariu, and C. Stanciu, “Helicobacter pylori infection in patients with diabetes mellitus,” Revista Mcedico-Hirurgicala a Societatii de Medici si Naturalisti din Iasi's, vol. 107, no. 1, pp. 59–65, 2003. View at: Google Scholar
  30. S. A. Hamed, N. F. Amine, G. M. Galal et al., “Vascular risks and complications in diabetes mellitus: the role of Helicobacter pylori infection,” Journal of Stroke and Cerebrovascular Diseases, vol. 17, no. 2, pp. 86–94, 2008. View at: Publisher Site | Google Scholar
  31. R. Buzzetti, S. Di Pietro, A. Giaccari et al., “High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes,” Diabetes Care, vol. 30, no. 4, pp. 932–938, 2007. View at: Publisher Site | Google Scholar
  32. P. Monti, M. Scirpoli, A. Rigamonti et al., “Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes,” The Journal of Immunology, vol. 179, no. 9, pp. 5785–5792, 2007. View at: Publisher Site | Google Scholar
  33. M. Songini, M. Loche, S. Muntoni et al., “Increasing prevalence of juvenile onset type 1 (insulin-dependent) diabetes mellitus in Sardinia: the military service approach,” Diabetologia, vol. 36, no. 6, pp. 547–552, 1993. View at: Publisher Site | Google Scholar
  34. Y. Yamaoka, T. Kudo, H. Lu, A. Casola, A. R. Brasier, and D. Y. Graham, “Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection,” Gastroenterology, vol. 126, no. 4, pp. 1030–1043, 2004. View at: Publisher Site | Google Scholar
  35. T. Borody, Z. Ren, G. Pang, and R. Clancy, “Impaired host immunity contributes to Helicobacter pylori eradication failure,” The American Journal of Gastroenterology, vol. 97, no. 12, pp. 3032–3037, 2002. View at: Publisher Site | Google Scholar
  36. D. A. de Luis, H. de la Calle, G. Roy et al., “Helicobacter pylori infection and insulin-dependent diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 39, no. 2, pp. 143–146, 1998. View at: Publisher Site | Google Scholar
  37. P. L. Jeffery, M. A. McGuckin, and S. K. Linden, “Endocrine impact of Helicobacter pylori: focus on ghrelin and ghrelin o-acyltransferase,” World Journal of Gastroenterology, vol. 17, no. 10, pp. 1249–1260, 2011. View at: Publisher Site | Google Scholar
  38. J. Roper, F. Francois, P. L. Shue et al., “Leptin and ghrelin in relation to Helicobacter pylori status in adult males,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 6, pp. 2350–2357, 2008. View at: Publisher Site | Google Scholar
  39. H. Kaneko, T. Konagaya, and K. Kusugami, “Helicobacter pylori and gut hormones,” Journal of Gastroenterology, vol. 37, no. 2, pp. 77–86, 2002. View at: Publisher Site | Google Scholar
  40. J. S. Muhammad, T. Sugiyama, and S. F. Zaidi, “Gastric pathophysiological Ins and outs of helicobacter pylori: a review,” Journal of the Pakistan Medical Association, vol. 63, no. 12, pp. 1528–1533, 2013. View at: Google Scholar
  41. L. Frulloni, C. Lunardi, R. Simone et al., “Identification of a novel antibody associated with autoimmune pancreatitis,” The New England Journal of Medicine, vol. 361, no. 22, pp. 2135–2142, 2009. View at: Publisher Site | Google Scholar
  42. D. Y. Graham, “Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits,” Gastroenterology, vol. 148, no. 4, pp. 719.e3–731.e3, 2015. View at: Publisher Site | Google Scholar
  43. M. P. Dore, A. R. Sepulveda, P. P. Bacciu et al., “Detection of Chlamydiae pneumoniae but not Helicobacter pylori DNA in atherosclerosis plaques,” Digestive Diseases and Sciences, vol. 48, no. 5, pp. 945–951, 2003. View at: Publisher Site | Google Scholar
  44. F. Franceschi, A. R. Sepulveda, A. Gasbarrini et al., “Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis,” Circulation, vol. 106, no. 4, pp. 430–434, 2002. View at: Publisher Site | Google Scholar

Copyright © 2016 Alessandro P. Delitala et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.